LON:DDDD 4D pharma (DDDD) Share Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free DDDD Stock Alerts GBX 16.66 0.00 (0.00%) (As of 11/8/2022) Add Compare Share Share Today's Range 16.66▼ 16.6650-Day Range 16.66▼ 16.6652-Week Range 16.66▼ 16.66Volume1.21 million shsAverage Volume2.96 million shsMarket Capitalization£30.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get 4D pharma alerts: Email Address Ad DTIWhat is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About 4D pharma Stock (LON:DDDD)4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Read More DDDD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DDDD Stock News HeadlinesMarch 1, 2024 | markets.businessinsider.com4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)February 7, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About 4D Molecular TherapeuticsApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 7, 2024 | msn.com4D Molecular Therapeutics up 3%, prices $300M equityFebruary 5, 2024 | marketwatch.com4D Molecular Shares Hit 52-Week High After 4D-150 Eye Treatment TrialFebruary 5, 2024 | realmoney.thestreet.comHow to Trade a Surging 4D Molecular TherapeuticsFebruary 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)February 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Valeo Pharma (OtherVPHIF) and AbbVie (ABBV)April 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… January 30, 2024 | news.yahoo.comIndian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businessesNovember 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), 4D Molecular Therapeutics (FDMT) and Inari Medical (NARI)November 11, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xenon (XENE), Adverum Biotechnologies (ADVM) and 4D Molecular Therapeutics (FDMT)November 2, 2023 | markets.businessinsider.comPositive Clinical Trial Results and Future Prospects Reinforce Buy Rating for 4D Molecular Therapeutics: An Analysis by Geulah LivshitsJuly 11, 2023 | markets.businessinsider.comBMO Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)July 5, 2023 | msn.com4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says AnalystApril 28, 2023 | marketwatch.com4D Molecular Down 25% After Wet AMD Drug UpdateApril 27, 2023 | markets.businessinsider.comWhat's Going On With 4D Molecular Therapeutics Stock TodayMarch 24, 2023 | marketwatch.comMicrobiome Therapeutics Market Current Trends, Segmentation, Key Players and Analysis Till 2035February 14, 2023 | marketwatch.comPharmacy Management System Market Scenario 2023 to 2028: New Developments, Economic Situation and Growth ProjectionJanuary 20, 2023 | finance.yahoo.comHuman Microbiome Market Report (2022 to 2030) – Obiome, 4D Pharma, Vedanta Biosciences, Second Genome, Ferring PharmaceuticalsDecember 30, 2022 | thetimes.co.uk4D Pharma rescue by Armistice to face voteOctober 5, 2022 | finance.yahoo.com4D pharma plc (DDDD.L)September 26, 2022 | nasdaq.comThe past year for 4D Molecular Therapeutics (NASDAQ:FDMT) investors has not been profitableJune 30, 2022 | apnews.com4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqJune 25, 2022 | thetimes.co.ukWoodford stock pick 4D Pharma collapsesJune 24, 2022 | finance.yahoo.comUpdate on Suspension of TradingMay 27, 2022 | proactiveinvestors.com.au4D Pharma outlines phase II plans for promising cancer drug candidateSee More Headlines Receive DDDD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:DDDD CUSIPN/A CIKN/A Webwww.4dpharmaplc.com Phone+44-113-8950130FaxN/AEmployees106Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-31,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-89.48% Return on Assets-42.64% Debt Debt-to-Equity Ratio39.50 Current Ratio5.21 Quick Ratio4.72 Sales & Book Value Annual Sales£718,000.00 Price / Sales41.84 Cash FlowGBX 11.60 per share Price / Cash Flow1.44 Book ValueGBX 18 per share Price / Book0.93Miscellaneous Outstanding Shares180,340,000Free FloatN/AMarket Cap£30.04 million OptionableNot Optionable Beta2.63 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Duncan Joseph Peyton (Age 53)CEO & Exec. Director Comp: $254kDr. Alexander James Stevenson Ph.D. (Age 51)Chief Scientific Officer & Exec. Director Comp: $218kMr. John Brendan Doyle (Age 45)Chief Financial Officer Ms. Fay WestonHead of Investor RelationsMr. Adrian MurrayGen. Counsel (Interim)Mr. Glenn DouradoExec. VP of Corp. Devel.Ms. Lucy ChristieVP of HRMr. Christophe CariteSr. VP of CMC & Process Devel.Ms. Imke MulderExec. VP of ResearchMore ExecutivesKey CompetitorsCollagen Solutions plc (COS.L)LON:COSBiodexa PharmaceuticalsLON:MTPHSareumLON:SAROKYO PharmaLON:OKYOC4X DiscoveryLON:C4XDView All Competitors DDDD Stock Analysis - Frequently Asked Questions How have DDDD shares performed in 2024? 4D pharma's stock was trading at GBX 16.66 at the beginning of 2024. Since then, DDDD stock has increased by 0.0% and is now trading at GBX 16.66. View the best growth stocks for 2024 here. How were 4D pharma's earnings last quarter? 4D pharma plc (LON:DDDD) released its quarterly earnings results on Wednesday, September, 30th. The company reported ($14.06) earnings per share for the quarter. What other stocks do shareholders of 4D pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other 4D pharma investors own include Amigo (AMGO), Adamis Pharmaceuticals (ADMP), American Airlines Group (AAL), Boeing (BA), Cineworld Group (CINE), Cray (CRAY), Omega Diagnostics Group (ODX), Oracle (ORCL), Tullow Oil (TLW). How do I buy shares of 4D pharma? Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DDDD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.